Literature DB >> 19498324

Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.

M Ozkaya1, M Sahin, E Cakal, F Yuzbasioglu, K Sezer, M Kilinc, S Simsek Imrek.   

Abstract

Alterations in thyroid function are associated with changes in body weight, metabolism, and low-grade inflammation. In several studies, plasma levels of visfatin were found to be associated with body mass index, diabetes, and metabolic syndrome. In our study we aimed to evaluate visfatin levels according to thyroid dysfunction. The study cohort comprised 56 Hashimoto thyroiditis patients with hypothyroidism (43.94+/-14.27 yr), 56 Graves patients with hyperthyroidism (45.87+/-13.28 yr), and 56 euthyroid healthy subjects (45.23+/-7.11 yr) as a control group. In addition, we evaluated the effect of therapy on plasma visfatin levels in 16 hypothyroid and in 25 hyperthyroid patients. Markedly low visfatin levels were found in hyperthyroid patients [9.44 (8.07- 10.8) ng/ml] compared with the hypothyroid [49.93 (40.72- 59.1) ng/ml] and control groups [38.6 (30.6-46.6) ng/ml] (p<0.001, p<0.001). Plasma visfatin levels in patients with hypothyroidism decreased significantly following treatment [58.58 (10.21-190.7) ng/ml vs 40.00 (10.01-102.6) ng/ml; p=0.001]. Plasma visfatin levels increased significantly after antithyroid therapy in patients with hyperthyroidism [7.86 (1.02-19.23) ng/ml vs 12.63 (3.48-110.9) ng/ml; p<0.001]. There were negative correlations between visfatin levels with free T3 (r=-0.719, p<0.001), and free T4 (r=-0.716, p<0.001) levels. There was a positive correlation between visfatin and TSH levels (r=0.701, p<0.001). There was a negative correlation between delta visfatin levels with delta free T3, delta free T4 (r=-0.686, p<0.001; r=-0.624, p<0.001). Visfatin thus seems to be regulated by thyroid hormones. While the influence of thyroid dysfunction on adipocytokine production and release is still poorly understood, the results of our study suggest that the effects of hyper- and hypothyroidism on various metabolic parameters may be partly mediated by visfatin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498324     DOI: 10.1007/BF03346482

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

Review 1.  Thyroid hormone excess and glucose intolerance.

Authors:  G D Dimitriadis; S A Raptis
Journal:  Exp Clin Endocrinol Diabetes       Date:  2001       Impact factor: 2.949

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes.

Authors:  Susan Kralisch; Johannes Klein; Ulrike Lossner; Matthias Bluher; Ralf Paschke; Michael Stumvoll; Mathias Fasshauer
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-05-17       Impact factor: 4.310

4.  Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.

Authors:  Vijayalakshmi Varma; Aiwei Yao-Borengasser; Neda Rasouli; Angela M Bodles; Bounleut Phanavanh; Mi-Jeong Lee; Tasha Starks; Leslie M Kern; Horace J Spencer; Robert E McGehee; Susan K Fried; Philip A Kern
Journal:  J Clin Endocrinol Metab       Date:  2006-11-07       Impact factor: 5.958

5.  Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.

Authors:  Miao-Pei Chen; Fu-Mei Chung; Dao-Ming Chang; Jack C-R Tsai; Han-Fen Huang; Shyi-Jang Shin; Yau-Jiunn Lee
Journal:  J Clin Endocrinol Metab       Date:  2005-10-18       Impact factor: 5.958

6.  Molecular characteristics of serum visfatin and differential detection by immunoassays.

Authors:  Antje Körner; Antje Garten; Matthias Blüher; Roy Tauscher; Jürgen Kratzsch; Wieland Kiess
Journal:  J Clin Endocrinol Metab       Date:  2007-09-18       Impact factor: 5.958

Review 7.  Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions.

Authors:  S Pilz; H Mangge; B Obermayer-Pietsch; W März
Journal:  J Endocrinol Invest       Date:  2007-02       Impact factor: 4.256

8.  Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.

Authors:  R MacLaren; W Cui; K Cianflone
Journal:  Diabetes Obes Metab       Date:  2007-07       Impact factor: 6.577

9.  Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.

Authors:  Pedro Iglesias; Pilar Alvarez Fidalgo; Rosa Codoceo; Juan J Díez
Journal:  Clin Endocrinol (Oxf)       Date:  2003-11       Impact factor: 3.478

10.  Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment.

Authors:  I Celik; S Akalin; T Erbaş
Journal:  Eur J Endocrinol       Date:  1995-06       Impact factor: 6.664

View more
  10 in total

1.  The Association Between Three Adipocytokines (Adiponectin, Resistin and Visfatin) And Thyroid Status in Patients With Type 2 Diabetes Mellitus and Autoimmune Thyroiditis.

Authors:  Š Sotak; Z Schroner; I Lazúrová; M Felšőci; I Jochmanová; D Petrášová; I Bertková; M Mitníková; B Nováková; H Wagnerová; O Bobelová
Journal:  Physiol Res       Date:  2021-10-30       Impact factor: 1.881

Review 2.  Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review.

Authors:  Ahad Eshraghian; Alireza Hamidian Jahromi
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

3.  Visfatin level in children and adolescents with autoimmune thyroiditis.

Authors:  Hekma Saad Farghaly; Kotb Abbass Metwalley; Faisal-Alkhateeb Ahmed; Duaa Mohamed Raafat; Osama El-Asheer; Ahmed Mahmood Ali; Ahlam Bahdawy; Asmaa Mohamed Zahran
Journal:  Ther Adv Endocrinol Metab       Date:  2017-09-25       Impact factor: 3.565

4.  Histopathologic Evaluation of Nonalcoholic Fatty Liver Disease in Hypothyroidism-Induced Rats.

Authors:  Şule Demir; Mustafa Ünübol; Serap Ünübol Aypak; Emrah İpek; Serdar Aktaş; Gamze Sevri Ekren; Murat Yılmaz; Recai Tunca; Engin Güney
Journal:  Int J Endocrinol       Date:  2016-04-07       Impact factor: 3.257

5.  The potential influence of hyperthyroidism on circulating adipokines chemerin, visfatin, and omentin.

Authors:  Eman M Alshaikh; Ulfat M Omar; Hadeil M Alsufiani; Rasha A Mansouri; Nesrin I Tarbiah; Abdelrhman A Alshaikh; Sawsan A Rahimulddin; Huda A Al Doghaither
Journal:  Int J Health Sci (Qassim)       Date:  2019 Mar-Apr

Review 6.  Adipocytokines in thyroid dysfunction.

Authors:  Berna İmge Aydogan; Mustafa Sahin
Journal:  ISRN Inflamm       Date:  2013-06-23

7.  Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: An experimental and clinical update.

Authors:  Nese Cinar; Alper Gurlek
Journal:  Endocr Connect       Date:  2013-10-24       Impact factor: 3.335

8.  Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.

Authors:  Nadia Sawicka-Gutaj; Bartłomiej Budny; Ariadna Zybek-Kocik; Jerzy Sowiński; Katarzyna Ziemnicka; Joanna Waligórska-Stachura; Marek Ruchała
Journal:  Endocrine       Date:  2016-01-14       Impact factor: 3.633

9.  Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.

Authors:  Nadia Sawicka-Gutaj; Ariadna Zybek-Kocik; Aleksandra Klimowicz; Michał Kloska; Dorota Mańkowska-Wierzbicka; Jerzy Sowiński; Marek Ruchała
Journal:  Int J Endocrinol       Date:  2016-01-17       Impact factor: 3.257

10.  Adipocytokines in Graves' orbitopathy and the effect of high-dose corticosteroids.

Authors:  Jan Schovanek; Michal Krupka; Lubica Cibickova; Marta Karhanova; Sunaina Reddy; Veronika Kucerova; Zdenek Frysak; David Karasek
Journal:  Adipocyte       Date:  2021-12       Impact factor: 4.534

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.